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background:  There is a paucity of data on cardiovascular outcomes in patients with end-stage renal disease (ESRD) after implantation of 
an implantable cardiac defibrillator (ICD) or cardiac resynchronization therapy (CRT).
Methods:  We enrolled 7,825 Kaiser Permanente members across 6 geographical regions of the United States between 1/1/2007 and 
12/31/2013. The exposure of interest was patients with ESRD compared to non-ESRD. The primary outcome was all-cause mortality. 
Multivariable Cox proportional hazards model was utilized for analysis.
results:  Patients with ESRD constituted 4.0% of the entire cohort. The median age was 65.8 years with 26.4% women. Hematomas 
(p=0.048), early device replacement (p<0.001) and late device infections (p<0.0001) occurred more frequently in ESRD with no significant 
difference in tamponade, pneumothorax, or early device infections. 5-year survival was significantly worse in ESRD patients (figure). ESRD 
was associated with a risk-adjusted hazard ratio of 3.02 for mortality (95% CI: 2.53 - 3.62) with age, gender and other covariates in the 
model significantly associated with mortality. Interestingly, neither age (p=0.076) nor other covariates were associated with mortality in a 
model restricted to only ESRD patients.
Conclusion:  Patients with ESRD continue to be a high-risk cohort for the development of early and late complications after ICD or CRT 
therapy. Further research is needed to identify those who will maximally benefit.
